Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Aasly, Jan O ^a,b   Johansen, Krisztina K ^a   Brønstad, Gunnar ^b   Warø, Bjørg J ^a,b   Majbour, Nour K ^c   Varghese, Shiji ^c   Alzahmi, Fatimah ^c   Paleologou, Katerina E ^d   Amer, Dena A M ^c   Al Hayani, Abdulmonem ^e   El Agnaf, Omar M A ^c,e  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alpha synuclien; Biomarkers; CSF; LRRK2 mutation carriers; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; OLIGOMER;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 84907162800     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00248     Document Type: Article

References (35)

1. Aasly, J. O., Toft, M., Fernandez-Mata, I., Kachergus, J., Hulihan, M., White, L. R., & Farrer, M. (2005). Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol, 57(5), 762-765. doi: 10.1002/ana.20456
2. Aasly, J. O., Vilariño-Gu¨ell, C., Dachsel, J. C., Webber, P. J., West, A. B., Haugarvoll, K., Farrer, M. J. (2010). Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov Disord, 25(13), 2156-2163. doi: 10.1002/mds.23265
3. Di Fonzo, A., Rohe´, C. F., Ferreira, J., Chien, H. F., Vacca, L., Stocchi, F., Network, I. P. G. (2005). A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, 365(9457), 412-415. doi: 10.1016/S0140-6736(05)17829-5
4. Da¨chsel, J. C., & Farrer, M. J. (2010). LRRK2 and Parkinson disease. Arch Neurol, 67(5), 542-547. doi: 10.1001/archneurol.2010.79
5. El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, 334 N. J., Gibson, M. J., Allsop, D. (2003). Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J, 17(13), 1945-1947. doi: 10.1096/fj.03-0098fje
6. El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Allsop, D. (2006). Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J, 20(3), 419-425. doi: 10.1096/fj.03-1449com
7. Ferree, A., Guillily, M., Li, H., Smith, K., Takashima, A., Squillace, R., Wolozin, B. (2012). Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener Dis, 10(1-4), 238-241. doi: 10.1159/000332599
8. Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Wood, N. W. (2005). A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 365(9457), 415-416. doi: 10.1016/S0140-6736(05)17830-1
9. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Zhang, J. (2010). DJ-1 and alpha347 synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133(Pt 3), 713-726. doi: 10.1093/brain/awq008
10. Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008). Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med, 14(7-8), 451-464. doi: 10.2119/2007-00100.Irvine
11. Johansen, K. K., Hasselberg, K., White, L. R., Farrer, M. J., & Aasly, J. O. (2010). Genealogical studies in LRRK2- associated Parkinson's disease in central Norway. Parkinsonism Relat Disord, 16(8), 527-530. doi: 10.1016/j.parkreldis.2010.05.005
12. Johansen, K. K., White, L. R., Farrer, M. J., & Aasly, J. O. (2011). Subclinical signs in LRRK2 mutation carriers. Parkinsonism Relat Disord, 17(7), 528-532. doi: 10.1016/j.parkreldis.2011.04.014
13. Kru¨ger, R., Kuhn, W., Mu¨ller, T., Woitalla, D., Graeber, M., Ko¨sel, S., Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18(2), 106-108. doi: 10.1038/ng0298-106
14. Lin, X., Parisiadou, L., Gu, X. L., Wang, L., Shim, H., Sun, L., Cai, H. (2009). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha362 synuclein. Neuron, 64(6), 807-827. doi: 10.1016/j.neuron.2009.11.006
15. Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Stoessl, A. J. (2008). Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology, 71(22), 1790-1795. doi: 10.1212/01.wnl.0000335973.66333.58
16. Nichols, W. C., Pankratz, N., Hernandez, D., Paisa´n-Rui´z, C., Jain, S., Halter, C. A., investigators, P. S. G.-P. (2005). Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet, 365(9457), 410-412. doi: 10.1016/S0140-6736(05)17828-3
17. Paleologou, K. E., Kragh, C. L., Mann, D. M., Salem, S. A., Al-Shami, R., Allsop, D., El-Agnaf, O. M. (2009). Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain, 132(Pt 4), 1093-1101. doi: 10.1093/brain/awn349
18. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H., & Kim, J. W. (2011). Elevated levels of a-synuclein oligomer in the cerebrospinal fluid of drug-nai¨ve patients with Parkinson's disease. J Clin Neurol, 7(4), 215-222. doi: 10.3988/jcn.2011.7.4.215
19. Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Calabresi, P. (2014). Cerebrospinal fluid lysosomal enzymes and a-synuclein in Parkinson's disease. Mov Disord. doi: 10.1002/mds.25772
20. Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., Calabresi, P. (2014). Differential role of CSF alpha-synuclein species, tau, and Aß42 in Parkinson's Disease. Front Aging Neurosci, 6, 53. doi: 10.3389/fnagi.2014.00053
21. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276(5321), 2045-2047.
22. Ruiz-Marti´nez, J., Gorostidi, A., Goyenechea, E., Alzualde, A., Poza, J. J., Rodri´guez, F., Marti´ Masso´, J. F. (2011). Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord, 26(11), 2026-2031. doi: 10.1002/mds.23773
23. Saunders-Pullman, R., Stanley, K., Wang, C., San Luciano, M., Shanker, V., Hunt, A., Bressman, S. B. (2011). Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology, 77(4), 319-324. doi: 10.1212/WNL.0b013e318227041c
24. Schapira, A. H. (1999). Science, medicine, and the future: Parkinson's disease. BMJ, 318(7179), 311-314.
25. Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Zhang, J. (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol, 69(3), 570-580. doi: 10.1002/ana.22311
26. Shi, M., Furay, A. R., Sossi, V., Aasly, J. O., Armaly, J., Wang, Y., Zhang, J. (2012). DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging, 33(4), 836.e835-837. doi: 10.1016/j.neurobiolaging.2011.09.015
27. Sierks, M. R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P., & Prasad, S. (2011). CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb), 3(12), 1188-1196. doi: 10.1039/c1ib00018g
28. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Gwinn-Hardy, K. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302(5646), 841. doi: 10.1126/science.1090278
29. Singleton, A. B., Farrer, M. J., & Bonifati, V. (2013). The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord, 28(1), 14-23. doi: 10.1002/mds.25249
30. Sossi, V., de la Fuente-Ferna´ndez, R., Nandhagopal, R., Schulzer, M., McKenzie, J., Ruth, T. J., Stoessl, J. A. (2010). Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord, 25(16), 2717-2723. doi: 10.1002/mds.23356
31. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha409 synuclein in Lewy bodies. Nature, 388(6645), 839-840. doi: 10.1038/42166
32. Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., El-Agnaf, O. M. (2010). Detection of elevated levels of a-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75(20), 1766-1772. doi: 10.1212/WNL.0b013e3181fd613b
33. Tong, Y., Giaime, E., Yamaguchi, H., Ichimura, T., Liu, Y., Si, H., Shen, J. (2012). Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener, 7, 2. doi: 10.1186/1750-1326-7-2
34. Wider, C., Dickson, D. W., & Wszolek, Z. K. (2010). Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis, 7(1-3), 175-179. doi: 10.1159/000289232
35. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Riek, R. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A, 108(10), 4194-4199. doi: 10.1073/pnas.1100976108